The early cellular signatures of protective immunity induced by live viral vaccination

European Journal of Immunology

Volumn 42, Issue 9, 2012, Pages 2363-2373

  Kohler, Siegfried ^a   Bethke, Nicole ^a   Böthe, Matthias ^b   Sommerick, Sophie ^a   Frentsch, Marco ^a   Romagnani, Chiara ^c   Niedrig, Matthias ^b   Thiel, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

Immune responses; Protective immunity; T cells; Vaccination; Yellow fever virus

Indexed keywords

CD19 ANTIGEN; INTERLEUKIN 6 RECEPTOR; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DENDRITIC CELL; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION; YELLOW FEVER FLAVIVIRUS;

ADAPTIVE IMMUNITY; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; MIDDLE AGED; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 84865799009     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201142306     Document Type: Article

References (29)

1. Theiler, M. and Smith, H. H., The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937. 65: 787-800.
2. Monath, T. P., Yellow fever: an update. Lancet. Infect. Dis. 2001. 1: 11-20.
3. Niedrig, M., Lademann, M., Emmerich, P. and Lafrenz, M., Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health. 1999. 4: 867-871.
4. Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S. et al., Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006. 203: 413-424.
5. Palmer, D. R., Fernandez, S., Bisbing, J., Peachman, K. K., Rao, M., Barvir, D., Gunther, V. et al., Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J. Gen. Virol. 2007. 88: 148-156.
6. Barba-Spaeth, G., Longman, R. S., Albert, M. L. and Rice, C. M., Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T-cell epitopes. J. Exp. Med. 2005. 202: 1179-1184.
7. Martins, M. A., Silva, M. L., Marciano, A. P., Peruhype-Magalhaes, V., Eloi-Santos, S. M., Ribeiro, G. L., Correa-Oliveira, R. et al., Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin. Exp. Immunol. 2007. 148: 90-100.
8. Gaucher, D., Therrien, R., Kettaf, N., Angermann, B. R., Boucher, G., Filali-Mouhim, A., Moser, J. M. et al., Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 2008. 205: 3119-3131.
9. Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K. et al., Human effector and memory CD8+ T-cell responses to smallpox and yellow fever vaccines. Immunity 2008. 28: 710-722.
10. Akondy, R. S., Monson, N. D., Miller, J. D., Edupuganti, S., Teuwen, D., Wu, H., Quyyumi, F. et al., The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T-cell response. J. Immunol. 2009. 183: 7919-7930.
11. Doisne, J. M., Urrutia, A., Lacabaratz-Porret, C., Goujard, C., Meyer, L., Chaix, M. L., Sinet, M. et al., CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J. Immunol. 2004. 173: 2410-2418.
12. Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A. et al., Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009. 10: 116-125.
13. Reinhardt, B., Jaspert, R., Niedrig, M., Kostner, C. and L'Age-Stehr, J., Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 1998. 56: 159-167.
14. Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W., Davey, D. F., Flynn, B. J., Hoff, S. T. et al., Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007. 13: 843-850.
15. Precopio, M. L., Betts, M. R., Parrino, J., Price, D. A., Gostick, E., Ambrozak, D. R., Asher, T. E. et al., Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T-cell responses. J. Exp. Med. 2007. 204: 1405-1416.
16. Seder, R. A., Darrah, P. A. and Roederer, M., T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008. 8: 247-258.
17. Brandriss, M. W., Schlesinger, J. J., Walsh, E. E. and Briselli, M., Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 1986. 67 (Pt 2): 229-234.
18. Pulendran, B. and Ahmed, R., Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006. 124: 849-863.
19. Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D. and Ahmed, R., Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 2003. 4: 1191-1198.
20. Odendahl, M., Mei, H., Hoyer, B. F., Jacobi, A. M., Hansen, A., Muehlinghaus, G., Berek, C. et al., Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005. 105: 1614-1621.
21. Tokoyoda, K., Zehentmeier, S., Hegazy, A. N., Albrecht, I., Grun, J. R., Lohning, M. and Radbruch, A., Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 2009. 30: 721-730.
22. Ehl, S., Hombach, J., Aichele, P., Hengartner, H. and Zinkernagel, R. M., Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J. Exp. Med. 1997. 185: 1241-1251.
23. Bangs, S. C., Baban, D., Cattan, H. J., Li, C. K., McMichael, A. J. and Xu, X. N., Human CD4+ memory T cells are preferential targets for bystander activation and apoptosis. J. Immunol. 2009. 182: 1962-1971.
24. Jones, S. A., Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 2005. 175: 3463-3468.
25. Wang, C., Tang, J., Song, W., Lobashevsky, E., Wilson, C. M. and Kaslow, R. A., HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004. 39: 978-988.
26. Reinartz, S., Hombach, A., Kohler, S., Schlebusch, H., Wallwiener, D., Abken, H. and Wagner, U., Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res. 2003. 63: 3234-3240.
27. Frentsch, M., Arbach, O., Kirchhoff, D., Moewes, B., Worm, M., Rothe, M., Scheffold, A. et al., Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat. Med. 2005. 11: 1118-1124.
28. Meier, S., Stark, R., Frentsch, M. and Thiel, A., The influence of different stimulation conditions on the assessment of antigen-induced CD154 expression on CD4+ T cells. Cytometry A 2008. 73: 1035-1042.
29. Reed, L. J., and Muench, H., A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938: 493-497.